174P First-in-human study of NGM707, an ILT2/ILT4 dual antagonist antibody in advanced or metastatic solid tumors: Preliminary monotherapy dose escalation data. (December 2022) - Naing, A.; Wang, J.S.; Sharma, M.R.; Sommerhalder, D.; Gandhi, L.; Oh, D-Y.; Jiang, Y.; Michalski, J.; Lee, J.; Zhou, K.; Taylor, N.; Yan, L.; et al.